InMed Pharmaceuticals (INM) Competitors $2.98 +0.03 (+1.02%) As of 04/30/2025 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. GLYC, ABVC, NRSN, COCP, PHIO, INAB, CLRB, ME, MBRX, and UPXIShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include GlycoMimetics (GLYC), ABVC BioPharma (ABVC), NeuroSense Therapeutics (NRSN), Cocrystal Pharma (COCP), Phio Pharmaceuticals (PHIO), IN8bio (INAB), Cellectar Biosciences (CLRB), 23andMe (ME), Moleculin Biotech (MBRX), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. GlycoMimetics ABVC BioPharma NeuroSense Therapeutics Cocrystal Pharma Phio Pharmaceuticals IN8bio Cellectar Biosciences 23andMe Moleculin Biotech Upexi GlycoMimetics (NASDAQ:GLYC) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings. Is GLYC or INM more profitable? GlycoMimetics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -163.75%. InMed Pharmaceuticals' return on equity of -90.74% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -230.74% -177.39% InMed Pharmaceuticals -163.75%-90.74%-71.70% Does the MarketBeat Community believe in GLYC or INM? GlycoMimetics received 309 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 57.85% of users gave GlycoMimetics an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGlycoMimeticsOutperform Votes31757.85% Underperform Votes23142.15% InMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% Do analysts rate GLYC or INM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, GLYC or INM? InMed Pharmaceuticals has higher revenue and earnings than GlycoMimetics. GlycoMimetics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K1,647.04-$37.88M-$0.59-0.43InMed Pharmaceuticals$4.83M0.74-$7.68M-$13.75-0.21 Which has more volatility & risk, GLYC or INM? GlycoMimetics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Does the media refer more to GLYC or INM? In the previous week, GlycoMimetics had 2 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 4 mentions for GlycoMimetics and 2 mentions for InMed Pharmaceuticals. GlycoMimetics' average media sentiment score of 0.72 beat InMed Pharmaceuticals' score of 0.44 indicating that GlycoMimetics is being referred to more favorably in the media. Company Overall Sentiment GlycoMimetics Positive InMed Pharmaceuticals Neutral Do insiders and institutionals believe in GLYC or INM? 75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 1.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryGlycoMimetics beats InMed Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.56M$6.87B$5.55B$7.75BDividend YieldN/A3.09%5.11%4.22%P/E Ratio-0.217.4322.4218.43Price / Sales0.74242.13393.41102.88Price / CashN/A65.8538.1834.62Price / Book0.586.506.724.23Net Income-$7.68M$143.21M$3.22B$248.23M7 Day PerformanceN/A3.37%2.66%2.79%1 Month Performance43.20%-0.18%-0.51%1.94%1 Year Performance-45.17%2.44%17.84%5.20% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals0.2795 of 5 stars$2.98+1.0%N/A-44.6%$3.60M$4.83M-0.2210Short Interest ↑Gap DownGLYCGlycoMimetics2.1306 of 5 stars$0.22-1.3%N/A-86.0%$14.19M$10,000.00-0.3750Short Interest ↓Gap UpABVCABVC BioPharma1.0933 of 5 stars$0.87+2.1%N/A-15.2%$13.77M$509,788.00-1.0130Earnings ReportPositive NewsNRSNNeuroSense Therapeutics1.1238 of 5 stars$1.00-3.2%N/A-27.4%$13.67MN/A-1.5610Short Interest ↓COCPCocrystal Pharma2.489 of 5 stars$1.34+1.9%$7.00+424.2%-4.4%$13.58MN/A-0.7210PHIOPhio Pharmaceuticals2.5701 of 5 stars$2.83+3.7%$4.00+41.3%-69.4%$13.52MN/A-0.2610Upcoming EarningsINABIN8bio3.6014 of 5 stars$0.17+3.3%$6.00+3,510.1%-83.4%$13.51MN/A-0.2220Upcoming EarningsShort Interest ↓CLRBCellectar Biosciences1.8098 of 5 stars$0.29-2.9%$12.50+4,207.4%-91.9%$13.37MN/A-0.1710Analyst ForecastNews CoverageGap DownME23andMeN/A$0.50-35.3%N/A-95.0%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeMBRXMoleculin Biotech3.1722 of 5 stars$0.95+8.6%$6.00+531.4%-78.9%$13.30MN/A0.0020Short Interest ↓News CoverageUPXIUpexi0.9616 of 5 stars$9.89+330.0%N/A+9.4%$13.07M$18.63M0.00130Short Interest ↑News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies GLYC Alternatives ABVC Alternatives NRSN Alternatives COCP Alternatives PHIO Alternatives INAB Alternatives CLRB Alternatives ME Alternatives MBRX Alternatives UPXI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
